Cognitive Labs

Researchers at Columbia detect differences in the brains of people carrying the APOE genetic marker who showed no symptoms and were not picked up by standard paper-based tests. Our research shows MemCheck to be sensitive in these situations. So, there is one more reason to start your program today if you have already taken one of our free tests.

Using brain imaging, researchers at Columbia University Medical Center (CUMC) have found clear differences in brain function between healthy people who carry a genetic risk factor for Alzheimer's disease and those who lack the factor.
Because researchers believe that Alzheimer's disease starts changing the brain years before any symptoms appear, the disease may be most amenable to treatment in these pre-clinical stages. If so, detecting the early changes will be crucial for future therapies.

People who carry the genetic risk factor, the e4 allele of the Apolipoprotein (APOE) gene, have higher risk of developing the disease than non-carriers and usually show symptoms earlier.

"It is possible that what we're seeing in the APOE-e4 carriers are early changes in the brain caused by Alzheimer's disease," says the study's senior author, Yaakov Stern, Ph.D., of CUMC's Taub Institute and Sergievsky Center.

But he and the study's first author, Nikolaos Scarmeas, M.D., caution that more research is needed before it's known for certain if the difference is an early sign of Alzheimer's. "It's also possible that the brain differences we see are related to the APOE gene but are not necessarily directly related to incipient Alzheimer's," says Dr. Scarmeas, a neurologist in the Taub Institute, Sergievsky Center and neurology department. "Even so, the differences we've found may provide information on how the å4 allele predisposes carriers to Alzheimer's disease."

The present study appears in the Nov.-Dec. 2004 issue of the American Journal of Geriatric Psychiatry.

// posted by neurofuture1:49 PM permanent link